Walleye Capital’s Relmada Therapeutics RLMD Stock Holding History

Walleye Capital’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-200	Closed	-$7K	–	3560
2022 Q3	$7K	Buy	+200	New	+$5.54K	﹤0.01%	2874

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Walleye Capital's RLMD Position: Q2 2026 in Review

Walleye Capital opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 616,238 shares worth $4.26M. The stake represents 0.02% of the portfolio and ranks #924 among its holdings. This is a return to the name: Walleye Capital previously reported a position in RLMD as recently as Q1 2023.

Walleye Capital first reported a position in RLMD in Q4 2021 and has held it in 6 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Walleye Capital held 616,238 shares of Relmada Therapeutics worth $4.26M as of Q2 2026.
Relmada Therapeutics was a new Walleye Capital position in Q2 2026.
Relmada Therapeutics made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #924 holding.
Walleye Capital first reported a position in Relmada Therapeutics in Q4 2021 and has held it in 6 quarters since.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.